-+ 0.00%
-+ 0.00%
-+ 0.00%

Immunic Expects Funding to Last Into Late 2027

PUBT·10/19/2026 11:40:51
Listen to the news
Immunic Expects Funding to Last Into Late 2027
  • Immunic expects funding to last into late 2027.
  • Two fully enrolled Phase 3 trials of vidofludimus calcium, totaling 2,221 patients, are expected to deliver top-line results by year-end 2026.
  • A U.S. regulatory submission is targeted for mid-2027, subject to positive results; potential approval is expected in 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.